FDA to weigh easing limits on unproven peptides FDA Peptide Update: Category 2 Removals Explained The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is FDA takes first step in possible reversal of ban on some peptides The Washington Post